本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ensysce Biosciences Inc.

0.3605
-0.0128-3.43%
成交量:28.12万
成交额:10.25万
市值:701.42万
市盈率:-0.13
高:0.3734
开:0.3734
低:0.3600
收:0.3733
52周最高:2.75
52周最低:0.2300
股本:1,945.68万
流通股本:1,535.52万
量比:0.55
换手率:1.83%
股息:- -
股息率:- -
每股收益(TTM):-2.7523
每股收益(LYR):-3.9790
净资产收益率:-1295.09%
总资产收益率:-185.51%
市净率:-8.97
市盈率(LYR):-0.09

数据加载中...

公司资料

公司名字:
Ensysce Biosciences Inc.
交易所:
NASDAQ
成立时间:
2003
员工人数:
9
公司地址:
7946 Ivanhoe Avenue,Suite 201,La Jolla,California,United States
邮编:
92037
电话:
传真:
- -
简介:
Ensysce Biosciences, Inc.于2003年4月在特拉华州注册成立。该公司是一家临床阶段的制药公司,致力于开发创新方案以缓解重度疼痛,同时降低阿片类药物误用、滥用和过量服用的风险。该公司目前正在研发旨在提高处方药安全性的候选产品。

董事

名称
职位
Bob Gower
Chairman and Independent Director
Lynn Kirkpatrick
President,Chief Executive Officer and Director
Adam S. Levin
Independent Director
Curtis Rosebraugh
Independent Director
Lee Rauch
Independent Director
Steve Martin
Independent Director
William Chang
Independent Director

股东

名称
职位
Lynn Kirkpatrick
President,Chief Executive Officer and Director
Jeffrey Millard
Chief Operating Officer
David Humphrey
Chief Financial Officer,Secretary and Treasurer
Geoffrey Birkett
Chief Commercial Officer
Linda Pestano
Chief Development Officer
William K. Schmidt
Chief Medical Officer